dc.contributor.author | Yuzbasioglu, Erdal | |
dc.contributor.author | Artunay, Ozgur | |
dc.contributor.author | Rasier, Rifat | |
dc.contributor.author | Sengul, Alper | |
dc.contributor.author | Bahcecioglu, Halil | |
dc.date.accessioned | 2019-08-13T12:10:23Z | |
dc.date.accessioned | 2019-08-13T16:05:10Z | |
dc.date.available | 2019-08-13T12:10:23Z | |
dc.date.available | 2019-08-13T16:05:10Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 0271-3683 | |
dc.identifier.uri | https://dx.doi.org/10.1080/02713680802710692 | |
dc.identifier.uri | http://hdl.handle.net/11446/3442 | |
dc.description | WOS: 000263992600009 | en_US |
dc.description | PubMed ID: 19274531 | en_US |
dc.description.abstract | Purpose: To evaluate and report the effectiveness, visual, anatomical, and clinical outcome of intravitreal bevacizumab (Avastin) injection in patients with retinitis pigmentosa (RP). Methods: Our prospective study included 13 eyes of 7 patients (4 women and 3 men) in the age range of 25-69 years (mean 44.14 years) with cystoid macular edema (CME) secondary to RP. Intravitreal bevacizumab at a dose of 1.25 mg/0.05 ml was injected via a 28-gauge needle. The response rate to treatment was monitored functionally by visual acuity assessment and anatomically using the optical coherence tomography. Results: The baseline mean central macular thickness was 370.15 m (range 245-603 m. The central macular thickness decreased to 142.53 m (range 124-168 m) after bevacizumab injections. The pre- and post-treatment visual acuity ranges were 5/400-20/100 and 20/200-20/63, respectively. Conclusions: Our data reveal that intravitreal bevacizumab administration is effective for the treatment of CME in RP. Further studies with a larger population and longer follow-up period are warranted to assess the efficacy of the treatment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | TAYLOR & FRANCIS INC | en_US |
dc.identifier.doi | 10.1080/02713680802710692 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Avastin | en_US |
dc.subject | intravitreal bevacizumab | en_US |
dc.subject | macular edema | en_US |
dc.subject | retinal dystrophies | en_US |
dc.subject | retinitis pigmentosa | en_US |
dc.title | Intravitreal Bevacizumab (Avastin) Injection in Retinitis Pigmentosa | en_US |
dc.type | article | en_US |
dc.relation.journal | CURRENT EYE RESEARCH | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.volume | 34 | en_US |
dc.identifier.startpage | 231 | en_US |
dc.identifier.endpage | 237 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Yuzbasioglu, Erdal -- Artunay, Ozgur -- Rasier, Rifat -- Sengul, Alper -- Bahcecioglu, Halil] Bilim Univ, Istanbul, Turkey | en_US |